Mirati

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Retrieved on: 
Thursday, June 22, 2023
Odyssey, Partnership, Drug development, Doctor of Philosophy, Stanford University, Crizotinib, ACRV, Schering-Plough, Mirati Therapeutics, Neoplasm, Breast, Medicine, AP3, Research, Bangladesh Technical Education Board, Lung, Development, Patient, Patent, Washington University School of Medicine, Growth, American Cancer Society, Axitinib, Phase, Therapy, Pharmaceutical industry, Pfizer, Mirati

“We are thrilled about Chuck’s appointment and look forward to his contributions to the board,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.

Key Points: 
  • “We are thrilled about Chuck’s appointment and look forward to his contributions to the board,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.
  • “Chuck is a highly accomplished leader in our industry who has excelled as both a business executive as well as a precision oncology drug developer.
  • He founded Mirati Therapeutics where he built a world class oncology team resulting in the approval of its best-in-class KRASG12C inhibitor.
  • Dr. Baum serves on the board of directors at PMV Pharmaceuticals, Inc., Odyssey Therapeutics and Poseida Therapeutics.

Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023

Retrieved on: 
Thursday, June 1, 2023
Mirati, Goldman Sachs Capital Partners, Webcast, Therapy, Goldman, Mirati Therapeutics, Conference, SAN, Pharmaceutical industry, Broadcasting

SAN DIEGO, June 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 on June 15 at 8:40 a.m. P.T.

Key Points: 
  • SAN DIEGO, June 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 on June 15 at 8:40 a.m. P.T.
  • David Meek , chief executive officer, will represent the company in a fireside chat at the conference.
  • Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Mirati.com .
  • A replay of the webcast will be made available following the event.

Mirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies

Retrieved on: 
Monday, May 8, 2023
Partnership, AACR, Drug development, Patient, SCRI, Mirati Therapeutics, Clinical trial, Cancer, American Association for Cancer Research, Human Development Innovation Fund, Research, Trial of the century, MD, Physician, SAN, Mirati, Inclusion, Health, Therapy, III, Sarah Cannon Research Institute, Pharmaceutical industry, Nursing

Ensuring equitable access to and participation in clinical studies requires improved awareness and targeted efforts to remove systemic barriers that may limit access to clinical studies for underrepresented patient groups.

Key Points: 
  • Ensuring equitable access to and participation in clinical studies requires improved awareness and targeted efforts to remove systemic barriers that may limit access to clinical studies for underrepresented patient groups.
  • As part of this partnership, Mirati and SCRI will implement practices and programs focused on removing obstacles to clinical study participation, including expanding physician and patient education and increasing access to community-based clinical trials.
  • Initiatives will be focused on reducing complexities associated with activating clinical trials thereby enabling a greater number of community practices to participate in research studies.
  • "The opportunity to partner with SCRI enables Mirati to advance diversity in our clinical studies, which is a key pillar of our Diversity, Equity, and Inclusion efforts.

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, May 5, 2023
Employment, Therapy, RSU, Mirati Therapeutics, SAN, Corporation, Pharmaceutical industry, Life insurance, Mirati

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Specifically, John Moriarty, newly appointed as Chief Legal Officer and Corporate Secretary received options to purchase 83,525 shares of Mirati's common stock and 49,363 restricted stock units ("RSUs").
  • In addition, the other employee received options to purchase 2,955 shares of Mirati's common stock, and 1,747 RSUs.
  • The options have an exercise price of $45.88 per share, which is equal to the closing price of Mirati's common stock on May 1, 2023, (the "Grant Date").

Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023

Retrieved on: 
Tuesday, April 25, 2023
Mirati, Therapy, Mirati Therapeutics, SAN, Communications satellite, Broadcasting, Cryptocurrency

SAN DIEGO, April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023.

Key Points: 
  • SAN DIEGO, April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023.
  • During a conference call at 4:30 p.m.
  • ET / 1:30 p.m. PT on May 9, company executives will provide company updates and review financial results.
  • A replay of the call will be available approximately 2 hours after the event has ended at the same website.

Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs

Retrieved on: 
Monday, April 3, 2023
MTAP, AACR, MTA, Neoplasm, SOS1, American Association for Cancer Research, Mirati Therapeutics, Experiment, Congress, EGFR, SAN, Mirati, Therapy, Poster, PRMT5, Pharmaceutical industry, Communications satellite

SAN DIEGO, April 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced a presentation demonstrating in preclinical models the ability of MRTX0902, a selective and potent SOS1 inhibitor, to enhance anti-tumor activity and overcome acquired resistance in combination with either adagrasib, a potent and selective KRASG12C inhibitor, or an epidermal growth factor receptor (EGFR)  inhibitor (e.g. osimertinib).

Key Points: 
  • Findings will be presented on April 17 at the American Association for Cancer Research (AACR 2023) Annual Congress as an oral presentation at 3:36 p.m. -3:51 p.m.
  • ET / 12:36 p.m.- 12:51 p.m. PT (Presentation #3499) during the Molecular Pathway Discovery and Translation in Solid Tumors mini session.
  • The full abstract for the presentation can be found here .
  • In addition, Mirati will share poster presentations featuring MRTX1719, the company's novel MTA cooperative PRMT5 inhibitor.

Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference

Retrieved on: 
Monday, March 6, 2023
Mirati Therapeutics, Conference, Therapy, Webcast, SAN, Mirati, Pharmaceutical industry, Broadcasting

SAN DIEGO, March 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Barclays Global Healthcare Conference on March 14 at 6:00 a.m. P.T.

Key Points: 
  • SAN DIEGO, March 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Barclays Global Healthcare Conference on March 14 at 6:00 a.m. P.T.
  • Ben Hickey , chief commercial officer, and Alan Sandler , chief medical officer, will represent the company in a fireside chat at the conference.
  • Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Mirati.com .
  • A replay of the webcast will be made available following the event.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Mirati Therapeutics, Inc. (MRTX) and Encourages Long-Term MRTX Investors to Contact the Firm

Retrieved on: 
Monday, February 27, 2023
Mirati, Mirati Therapeutics, Acquisition

PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Mirati Therapeutics, Inc. (NASDAQ: MRTX) on behalf of the company’s long-term investors.

Key Points: 
  • PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Mirati Therapeutics, Inc. (NASDAQ: MRTX) on behalf of the company’s long-term investors.
  • Mirati shareholders are encouraged to contact Kaskela Law LLC (Adrienne Bell, Esq.)
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation.
  • For additional information about Kaskela Law LLC please visit www.kaskelalaw.com .

Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023

Retrieved on: 
Tuesday, February 14, 2023
Mirati, SAN, Mirati Therapeutics, Therapy, Cryptocurrency, Broadcasting

SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will announce financial results for the fourth quarter and full year of 2022 along with recent corporate updates on February 28, 2023.

Key Points: 
  • SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will announce financial results for the fourth quarter and full year of 2022 along with recent corporate updates on February 28, 2023.
  • During a conference call at 4:30 p.m.
  • ET / 1:30 p.m. PT on February 28, company executives will provide company updates and review financial results.
  • A replay of the call will be available approximately 2 hours after the event has ended at the same website.

Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences

Retrieved on: 
Wednesday, February 1, 2023
Mirati, SAN, PT, Mirati Therapeutics, Therapy, Webcast, Conference

SAN DIEGO, Feb. 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate in two upcoming healthcare conferences.

Key Points: 
  • SAN DIEGO, Feb. 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate in two upcoming healthcare conferences.
  • ET at the Guggenheim Healthcare Talks: Oncology Day Conference.
  • Laurie Stelzer , chief financial officer, and Alan Sandler , chief medical officer, will represent the company in a fireside chat at the conference.
  • Laurie Stelzer , chief financial officer, and Ben Hickey , chief commercial officer, will represent the company in a fireside chat at the conference.